Are you over 18 and want to see adult content?
More Annotations
A complete backup of bolzanoairport.it
Are you over 18 and want to see adult content?
A complete backup of masaru-emoto.net
Are you over 18 and want to see adult content?
A complete backup of easterngraphics.com
Are you over 18 and want to see adult content?
A complete backup of tractorforum.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of blskymm.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of quadrinhosinglorios.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of projetasgarddiy.fr
Are you over 18 and want to see adult content?
A complete backup of electronic-star.hu
Are you over 18 and want to see adult content?
A complete backup of alltomstockholm.se
Are you over 18 and want to see adult content?
A complete backup of desigharelunuskhe.in
Are you over 18 and want to see adult content?
A complete backup of portarthurva.com
Are you over 18 and want to see adult content?
A complete backup of lifehealthcare.co.za
Are you over 18 and want to see adult content?
Text
SUPPORTCAREERS
BioMarin to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, April 29 at 4:30pm ET. March 20, 2021. BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society’s Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide. March 8, 2021.OUR PRODUCTS
Our Products. PALYNZIQ ® (pegvaliase-pqpz) Injection. Brineura ® (cerliponase alfa) Vimizim ® (elosulfase alfa) Kuvan ® (sapropterin dihydrochloride) Naglazyme ® (galsulfase) Aldurazyme ® (laronidase) Our Pipeline. Valoctocogene Roxaparvovec for Severe Hemophilia A.OUR LOCATIONS
BioMarin Pharmaceutical Inc. 770 Lindaro Street. San Rafael, CA 94901. Directions ›. Tel: +1 (415) 506-6700. E-mail: Media Relations. E-mail: Investor Relations. *Please direct all mail to the U.S. mailing address in Novato. BIOMARIN PROVIDES HIGHLIGHTS OF 5 YEARS OF CLINICAL DATA BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-GRANTS & DONATIONS
Grants. Grants provide funding for a variety of events, activities, and projects that benefit patients, the scientific or medical community, and/or public health in areas of legitimate interest toBioMarin.
MANUFACTURING EXCELLENCE BioMarin Technical Operations (TOPS) is an experienced, responsive and agile organization with a proud connection to our patients – developing and manufacturing safe and effective medicines that we consistently deliver to those in need. From enzyme to gene therapy, our owned manufacturing approach allows us to maintain the highestquality
INDEPENDENT MEDICAL EDUCATION Independent Medical Education funding supports accredited or non-accredited medical education activities for HCPs where content is not controlled or influenced by BioMarin. Independent Medical Education includes both CME and non-CME programs, and both may originate from similar types of organizations (e.g., hospitals, professional societies, or BIOMARIN ANNOUNCES POSITIVE PHASE 3 GENE THERAPY TRIAL SAN RAFAEL, Calif., Jan. 10, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A. This is the largest global Phase 3 study to date for any gene therapy in any indication, BIOMARIN COMPLETES FULL ENROLLMENT IN PHASE 2 STUDY OF SAN RAFAEL, Calif., March 3, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has completed full enrollment in a global Phase 2 randomized, placebo-controlled study of vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP) for children with achondroplasia, the most common form of SEC FILINGS : BIOMARIN Description. Date. Format. 8-K. Report of unscheduled material events or corporate event. Jun 1, 2021. Open Report of unscheduled material events or corporate event in HTML. Open Report of unscheduled material events or corporate event in DOC file. Open Report of unscheduled material events or corporate event in PDF file. BIOMARIN PHARMACEUTICAL INC.ABOUT USPRODUCTS/PIPELINEPATIENTS/PHYSICIANSINVESTORS/MEDIAFUNDING &SUPPORTCAREERS
BioMarin to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, April 29 at 4:30pm ET. March 20, 2021. BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society’s Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide. March 8, 2021.OUR PRODUCTS
Our Products. PALYNZIQ ® (pegvaliase-pqpz) Injection. Brineura ® (cerliponase alfa) Vimizim ® (elosulfase alfa) Kuvan ® (sapropterin dihydrochloride) Naglazyme ® (galsulfase) Aldurazyme ® (laronidase) Our Pipeline. Valoctocogene Roxaparvovec for Severe Hemophilia A.OUR LOCATIONS
BioMarin Pharmaceutical Inc. 770 Lindaro Street. San Rafael, CA 94901. Directions ›. Tel: +1 (415) 506-6700. E-mail: Media Relations. E-mail: Investor Relations. *Please direct all mail to the U.S. mailing address in Novato. BIOMARIN PROVIDES HIGHLIGHTS OF 5 YEARS OF CLINICAL DATA BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-GRANTS & DONATIONS
Grants. Grants provide funding for a variety of events, activities, and projects that benefit patients, the scientific or medical community, and/or public health in areas of legitimate interest toBioMarin.
MANUFACTURING EXCELLENCE BioMarin Technical Operations (TOPS) is an experienced, responsive and agile organization with a proud connection to our patients – developing and manufacturing safe and effective medicines that we consistently deliver to those in need. From enzyme to gene therapy, our owned manufacturing approach allows us to maintain the highestquality
INDEPENDENT MEDICAL EDUCATION Independent Medical Education funding supports accredited or non-accredited medical education activities for HCPs where content is not controlled or influenced by BioMarin. Independent Medical Education includes both CME and non-CME programs, and both may originate from similar types of organizations (e.g., hospitals, professional societies, or BIOMARIN ANNOUNCES POSITIVE PHASE 3 GENE THERAPY TRIAL SAN RAFAEL, Calif., Jan. 10, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A. This is the largest global Phase 3 study to date for any gene therapy in any indication, BIOMARIN COMPLETES FULL ENROLLMENT IN PHASE 2 STUDY OF SAN RAFAEL, Calif., March 3, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has completed full enrollment in a global Phase 2 randomized, placebo-controlled study of vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP) for children with achondroplasia, the most common form of SEC FILINGS : BIOMARIN Description. Date. Format. 8-K. Report of unscheduled material events or corporate event. Jun 1, 2021. Open Report of unscheduled material events or corporate event in HTML. Open Report of unscheduled material events or corporate event in DOC file. Open Report of unscheduled material events or corporate event in PDF file. INDEPENDENT MEDICAL EDUCATION Independent Medical Education funding supports accredited or non-accredited medical education activities for HCPs where content is not controlled or influenced by BioMarin. Independent Medical Education includes both CME and non-CME programs, and both may originate from similar types of organizations (e.g., hospitals, professional societies, or BIOMARIN ANNOUNCES POSITIVE PHASE 3 GENE THERAPY TRIAL SAN RAFAEL, Calif., Jan. 10, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A. This is the largest global Phase 3 study to date for any gene therapy in any indication, BIOMARIN COMPLETES FULL ENROLLMENT IN PHASE 2 STUDY OF SAN RAFAEL, Calif., March 3, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has completed full enrollment in a global Phase 2 randomized, placebo-controlled study of vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP) for children with achondroplasia, the most common form of PHENYLKETONURIA (PKU): DISEASE AND CONDITIONS Phenylketonuria (PKU) is an inherited metabolic disorder caused by a deficiency of the enzyme phenylalanine hydroxylase (PAH). This enzyme is required for the breakdown of phenylalanine (Phe), an amino acid found in all protein-containing foods. When PAH is deficient or defective, Phe accumulates to abnormally high levels in the blood. GLOBAL MEDICAL INFORMATION Submit a question or request. By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical FDA REVIEW OF VOSORITIDE PROCEEDING; PDUFA TARGET ACTION Clinical Development ProgramUpdate. April 2021. MMRC-VOS-00069 2021BioMarin Pharmaceutical, Inc. | biomarin.com Ongoing Studies,Enrollment Complete
ACHONDROPLASIA CLINICAL TRIALS A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia, Age 0 to < 60 Months. Evaluate the safety and efficacy of BMN 111 in infants and young children.KEVIN EGGAN, PH.D.
Kevin Eggan, Ph.D., joined BioMarin in October 2020 and serves as Group Vice President, Head of Research and Early Development. He is responsible for the execution of BioMarin’s discovery research programs, helping to shape the vision and long-term growth of our company through the oversight of an exceptional research pipeline of first- or best-in-class therapies. VOSORITIDE FOR ACHONDROPLASIA Vosoritide is an investigational analog of C-type Natriuretic Peptide (CNP) under evaluation for the treatment of children with achondroplasia, the most common form of skeletal dysplasia. Vosoritide is being tested in children whose growth plates are still “open,” typically those under 18 years of age. BENEFITS AT BIOMARIN These things shape the work experience and provide a powerful connection between who you are, the work you do, and the life-changing hope it delivers. As a biopharmaceutical company, our success stems from our unwavering focus on science and the hope our therapies can bring to patients and their families. BIOMARIN PHARMACEUTICAL INC.ABOUT USPRODUCTS/PIPELINEPATIENTS/PHYSICIANSINVESTORS/MEDIAFUNDING &SUPPORTCAREERS
BioMarin to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, April 29 at 4:30pm ET. March 20, 2021. BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society’s Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide. March 8, 2021.OUR PRODUCTS
Our Products. PALYNZIQ ® (pegvaliase-pqpz) Injection. Brineura ® (cerliponase alfa) Vimizim ® (elosulfase alfa) Kuvan ® (sapropterin dihydrochloride) Naglazyme ® (galsulfase) Aldurazyme ® (laronidase) Our Pipeline. Valoctocogene Roxaparvovec for Severe Hemophilia A.OUR LOCATIONS
BioMarin Pharmaceutical Inc. 770 Lindaro Street. San Rafael, CA 94901. Directions ›. Tel: +1 (415) 506-6700. E-mail: Media Relations. E-mail: Investor Relations. *Please direct all mail to the U.S. mailing address in Novato. BIOMARIN PROVIDES HIGHLIGHTS OF 5 YEARS OF CLINICAL DATA BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-GRANTS & DONATIONS
Grants. Grants provide funding for a variety of events, activities, and projects that benefit patients, the scientific or medical community, and/or public health in areas of legitimate interest toBioMarin.
MANUFACTURING EXCELLENCE BioMarin Technical Operations (TOPS) is an experienced, responsive and agile organization with a proud connection to our patients – developing and manufacturing safe and effective medicines that we consistently deliver to those in need. From enzyme to gene therapy, our owned manufacturing approach allows us to maintain the highestquality
INDEPENDENT MEDICAL EDUCATION Independent Medical Education funding supports accredited or non-accredited medical education activities for HCPs where content is not controlled or influenced by BioMarin. Independent Medical Education includes both CME and non-CME programs, and both may originate from similar types of organizations (e.g., hospitals, professional societies, or BIOMARIN ANNOUNCES POSITIVE PHASE 3 GENE THERAPY TRIAL SAN RAFAEL, Calif., Jan. 10, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A. This is the largest global Phase 3 study to date for any gene therapy in any indication, BIOMARIN COMPLETES FULL ENROLLMENT IN PHASE 2 STUDY OF SAN RAFAEL, Calif., March 3, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has completed full enrollment in a global Phase 2 randomized, placebo-controlled study of vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP) for children with achondroplasia, the most common form of SEC FILINGS : BIOMARIN Description. Date. Format. 8-K. Report of unscheduled material events or corporate event. Jun 1, 2021. Open Report of unscheduled material events or corporate event in HTML. Open Report of unscheduled material events or corporate event in DOC file. Open Report of unscheduled material events or corporate event in PDF file. BIOMARIN PHARMACEUTICAL INC.ABOUT USPRODUCTS/PIPELINEPATIENTS/PHYSICIANSINVESTORS/MEDIAFUNDING &SUPPORTCAREERS
BioMarin to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, April 29 at 4:30pm ET. March 20, 2021. BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society’s Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide. March 8, 2021.OUR PRODUCTS
Our Products. PALYNZIQ ® (pegvaliase-pqpz) Injection. Brineura ® (cerliponase alfa) Vimizim ® (elosulfase alfa) Kuvan ® (sapropterin dihydrochloride) Naglazyme ® (galsulfase) Aldurazyme ® (laronidase) Our Pipeline. Valoctocogene Roxaparvovec for Severe Hemophilia A.OUR LOCATIONS
BioMarin Pharmaceutical Inc. 770 Lindaro Street. San Rafael, CA 94901. Directions ›. Tel: +1 (415) 506-6700. E-mail: Media Relations. E-mail: Investor Relations. *Please direct all mail to the U.S. mailing address in Novato. BIOMARIN PROVIDES HIGHLIGHTS OF 5 YEARS OF CLINICAL DATA BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-GRANTS & DONATIONS
Grants. Grants provide funding for a variety of events, activities, and projects that benefit patients, the scientific or medical community, and/or public health in areas of legitimate interest toBioMarin.
MANUFACTURING EXCELLENCE BioMarin Technical Operations (TOPS) is an experienced, responsive and agile organization with a proud connection to our patients – developing and manufacturing safe and effective medicines that we consistently deliver to those in need. From enzyme to gene therapy, our owned manufacturing approach allows us to maintain the highestquality
INDEPENDENT MEDICAL EDUCATION Independent Medical Education funding supports accredited or non-accredited medical education activities for HCPs where content is not controlled or influenced by BioMarin. Independent Medical Education includes both CME and non-CME programs, and both may originate from similar types of organizations (e.g., hospitals, professional societies, or BIOMARIN ANNOUNCES POSITIVE PHASE 3 GENE THERAPY TRIAL SAN RAFAEL, Calif., Jan. 10, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A. This is the largest global Phase 3 study to date for any gene therapy in any indication, BIOMARIN COMPLETES FULL ENROLLMENT IN PHASE 2 STUDY OF SAN RAFAEL, Calif., March 3, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has completed full enrollment in a global Phase 2 randomized, placebo-controlled study of vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP) for children with achondroplasia, the most common form of SEC FILINGS : BIOMARIN Description. Date. Format. 8-K. Report of unscheduled material events or corporate event. Jun 1, 2021. Open Report of unscheduled material events or corporate event in HTML. Open Report of unscheduled material events or corporate event in DOC file. Open Report of unscheduled material events or corporate event in PDF file. INDEPENDENT MEDICAL EDUCATION Independent Medical Education funding supports accredited or non-accredited medical education activities for HCPs where content is not controlled or influenced by BioMarin. Independent Medical Education includes both CME and non-CME programs, and both may originate from similar types of organizations (e.g., hospitals, professional societies, or BIOMARIN ANNOUNCES POSITIVE PHASE 3 GENE THERAPY TRIAL SAN RAFAEL, Calif., Jan. 10, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A. This is the largest global Phase 3 study to date for any gene therapy in any indication, BIOMARIN COMPLETES FULL ENROLLMENT IN PHASE 2 STUDY OF SAN RAFAEL, Calif., March 3, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has completed full enrollment in a global Phase 2 randomized, placebo-controlled study of vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP) for children with achondroplasia, the most common form of PHENYLKETONURIA (PKU): DISEASE AND CONDITIONS Phenylketonuria (PKU) is an inherited metabolic disorder caused by a deficiency of the enzyme phenylalanine hydroxylase (PAH). This enzyme is required for the breakdown of phenylalanine (Phe), an amino acid found in all protein-containing foods. When PAH is deficient or defective, Phe accumulates to abnormally high levels in the blood. GLOBAL MEDICAL INFORMATION Submit a question or request. By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical FDA REVIEW OF VOSORITIDE PROCEEDING; PDUFA TARGET ACTION Clinical Development ProgramUpdate. April 2021. MMRC-VOS-00069 2021BioMarin Pharmaceutical, Inc. | biomarin.com Ongoing Studies,Enrollment Complete
ACHONDROPLASIA CLINICAL TRIALS A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia, Age 0 to < 60 Months. Evaluate the safety and efficacy of BMN 111 in infants and young children.KEVIN EGGAN, PH.D.
Kevin Eggan, Ph.D., joined BioMarin in October 2020 and serves as Group Vice President, Head of Research and Early Development. He is responsible for the execution of BioMarin’s discovery research programs, helping to shape the vision and long-term growth of our company through the oversight of an exceptional research pipeline of first- or best-in-class therapies. VOSORITIDE FOR ACHONDROPLASIA Vosoritide is an investigational analog of C-type Natriuretic Peptide (CNP) under evaluation for the treatment of children with achondroplasia, the most common form of skeletal dysplasia. Vosoritide is being tested in children whose growth plates are still “open,” typically those under 18 years of age. BENEFITS AT BIOMARIN These things shape the work experience and provide a powerful connection between who you are, the work you do, and the life-changing hope it delivers. As a biopharmaceutical company, our success stems from our unwavering focus on science and the hope our therapies can bring to patients and their families. BIOMARIN PHARMACEUTICAL INC.ABOUT USPRODUCTS/PIPELINEPATIENTS/PHYSICIANSINVESTORS/MEDIAFUNDING &SUPPORTCAREERS
BioMarin to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, April 29 at 4:30pm ET. March 20, 2021. BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society’s Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide. March 8, 2021.OUR PRODUCTS
Our Products. PALYNZIQ ® (pegvaliase-pqpz) Injection. Brineura ® (cerliponase alfa) Vimizim ® (elosulfase alfa) Kuvan ® (sapropterin dihydrochloride) Naglazyme ® (galsulfase) Aldurazyme ® (laronidase) Our Pipeline. Valoctocogene Roxaparvovec for Severe Hemophilia A.OUR LOCATIONS
BioMarin Pharmaceutical Inc. 770 Lindaro Street. San Rafael, CA 94901. Directions ›. Tel: +1 (415) 506-6700. E-mail: Media Relations. E-mail: Investor Relations. *Please direct all mail to the U.S. mailing address in Novato.GRANTS & DONATIONS
Grants. Grants provide funding for a variety of events, activities, and projects that benefit patients, the scientific or medical community, and/or public health in areas of legitimate interest toBioMarin.
BIOMARIN ANNOUNCES FOURTH QUARTER AND RECORD FULL-YEAR Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months EndedDecember
BIOMARIN PROVIDES HIGHLIGHTS OF 5 YEARS OF CLINICAL DATA BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-KEVIN EGGAN, PH.D.
Kevin Eggan, Ph.D., joined BioMarin in October 2020 and serves as Group Vice President, Head of Research and Early Development. He is responsible for the execution of BioMarin’s discovery research programs, helping to shape the vision and long-term growth of our company through the oversight of an exceptional research pipeline of first- or best-in-class therapies. BIOMARIN COMPLETES FULL ENROLLMENT IN PHASE 2 STUDY OF SAN RAFAEL, Calif., March 3, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has completed full enrollment in a global Phase 2 randomized, placebo-controlled study of vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP) for children with achondroplasia, the most common form of BIOMARIN ANNOUNCES POSITIVE PHASE 3 GENE THERAPY TRIAL SAN RAFAEL, Calif., Jan. 10, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A. This is the largest global Phase 3 study to date for any gene therapy in any indication,WORKING AT BIOMARIN
This BioMarin process requires an in person interview at one of our company locations and never requires payment or fees from job applicants. In the event you receive a suspicious email message about recruiting on behalf of BioMarin, do not provide any personal information or pay any fees. BIOMARIN PHARMACEUTICAL INC.ABOUT USPRODUCTS/PIPELINEPATIENTS/PHYSICIANSINVESTORS/MEDIAFUNDING &SUPPORTCAREERS
BioMarin to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, April 29 at 4:30pm ET. March 20, 2021. BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society’s Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide. March 8, 2021.OUR PRODUCTS
Our Products. PALYNZIQ ® (pegvaliase-pqpz) Injection. Brineura ® (cerliponase alfa) Vimizim ® (elosulfase alfa) Kuvan ® (sapropterin dihydrochloride) Naglazyme ® (galsulfase) Aldurazyme ® (laronidase) Our Pipeline. Valoctocogene Roxaparvovec for Severe Hemophilia A.OUR LOCATIONS
BioMarin Pharmaceutical Inc. 770 Lindaro Street. San Rafael, CA 94901. Directions ›. Tel: +1 (415) 506-6700. E-mail: Media Relations. E-mail: Investor Relations. *Please direct all mail to the U.S. mailing address in Novato.GRANTS & DONATIONS
Grants. Grants provide funding for a variety of events, activities, and projects that benefit patients, the scientific or medical community, and/or public health in areas of legitimate interest toBioMarin.
BIOMARIN ANNOUNCES FOURTH QUARTER AND RECORD FULL-YEAR Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended December 31, Twelve Months EndedDecember
BIOMARIN PROVIDES HIGHLIGHTS OF 5 YEARS OF CLINICAL DATA BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-KEVIN EGGAN, PH.D.
Kevin Eggan, Ph.D., joined BioMarin in October 2020 and serves as Group Vice President, Head of Research and Early Development. He is responsible for the execution of BioMarin’s discovery research programs, helping to shape the vision and long-term growth of our company through the oversight of an exceptional research pipeline of first- or best-in-class therapies. BIOMARIN COMPLETES FULL ENROLLMENT IN PHASE 2 STUDY OF SAN RAFAEL, Calif., March 3, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has completed full enrollment in a global Phase 2 randomized, placebo-controlled study of vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP) for children with achondroplasia, the most common form of BIOMARIN ANNOUNCES POSITIVE PHASE 3 GENE THERAPY TRIAL SAN RAFAEL, Calif., Jan. 10, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A. This is the largest global Phase 3 study to date for any gene therapy in any indication,WORKING AT BIOMARIN
This BioMarin process requires an in person interview at one of our company locations and never requires payment or fees from job applicants. In the event you receive a suspicious email message about recruiting on behalf of BioMarin, do not provide any personal information or pay any fees.OUR SCIENTISTS
Meet the team behind our pioneering science. At BioMarin, we dare to engage in iterative processes of scientific inquiry in order to fundamentally improve the lives of patients. BioMarin is home to a progressive team of world-recognized leaders in genomic, molecular, process, safety, and clinical sciences; visionaries in their fieldswho have
MANUFACTURING EXCELLENCE BioMarin Technical Operations (TOPS) is an experienced, responsive and agile organization with a proud connection to our patients – developing and manufacturing safe and effective medicines that we consistently deliver to those in need. From enzyme to gene therapy, our owned manufacturing approach allows us to maintain the highestquality
INVESTOR RELATIONS : BIOMARIN Email Alerts. May 27, 2021. BioMarin to Participate in Two Upcoming Virtual Investor Conferences. BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences. An audio webcast ofWORKING AT BIOMARIN
This BioMarin process requires an in person interview at one of our company locations and never requires payment or fees from job applicants. In the event you receive a suspicious email message about recruiting on behalf of BioMarin, do not provide any personal information or pay any fees. ACHONDROPLASIA CLINICAL TRIALS A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia, Age 0 to < 60 Months. Evaluate the safety and efficacy of BMN 111 in infants and young children. GLOBAL COMPLIANCE & ETHICS BioMarin’s Global Compliance & Ethics Program (the “Program”) is an enterprise-wide global initiative that addresses the seven elements discussed in the OIG Compliance Program Guidance for Pharmaceutical Manufacturers, as well as the tenets of the U.S. Federal Sentencing PHENYLKETONURIA (PKU): DISEASE AND CONDITIONS Phenylketonuria (PKU) is an inherited metabolic disorder caused by a deficiency of the enzyme phenylalanine hydroxylase (PAH). This enzyme is required for the breakdown of phenylalanine (Phe), an amino acid found in all protein-containing foods. When PAH is deficient or defective, Phe accumulates to abnormally high levels in the blood. VOSORITIDE FOR ACHONDROPLASIA Vosoritide is an investigational analog of C-type Natriuretic Peptide (CNP) under evaluation for the treatment of children with achondroplasia, the most common form of skeletal dysplasia. Vosoritide is being tested in children whose growth plates are still “open,” typically those under 18 years of age.BIOMARIN INVESTORS
2021-04-29-BioMarin-Announces-First-Quarter-2021-Financial-Results-and-Corporate-UpdatesGRANTS & DONATIONS
Grants. Grants provide funding for a variety of events, activities, and projects that benefit patients, the scientific or medical community, and/or public health in areas of legitimate interest toBioMarin.
BIOMARIN PHARMACEUTICAL INC.ABOUT USPRODUCTS/PIPELINEPATIENTS/PHYSICIANSINVESTORS/MEDIAFUNDING &SUPPORTCAREERS
BioMarin to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, April 29 at 4:30pm ET. March 20, 2021. BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society’s Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide. March 8, 2021.OUR PRODUCTS
Our Products. PALYNZIQ ® (pegvaliase-pqpz) Injection. Brineura ® (cerliponase alfa) Vimizim ® (elosulfase alfa) Kuvan ® (sapropterin dihydrochloride) Naglazyme ® (galsulfase) Aldurazyme ® (laronidase) Our Pipeline. Valoctocogene Roxaparvovec for Severe Hemophilia A.OUR LOCATIONS
BioMarin Pharmaceutical Inc. 770 Lindaro Street. San Rafael, CA 94901. Directions ›. Tel: +1 (415) 506-6700. E-mail: Media Relations. E-mail: Investor Relations. *Please direct all mail to the U.S. mailing address in Novato. INVESTOR RELATIONS : BIOMARIN Email Alerts. May 24, 2021. European Medicines Agency Grants BioMarin's Request for Accelerated Assessment of Valoctocogene Roxaparvovec for Treatment of Severe Hemophilia A. BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Medicines Agency (EMA) has granted its request for accelerated assessment of valoctocogeneGRANTS & DONATIONS
Grants. Grants provide funding for a variety of events, activities, and projects that benefit patients, the scientific or medical community, and/or public health in areas of legitimate interest toBioMarin.
LEADERSHIP TEAM
Under the leadership of Chairman and Chief Executive Officer, Mr. Jean-Jacques Bienaimé, BioMarin’s executive management team includes accomplished leaders with deep and broad executive experience. Supported by a staff of approximately 3,000 employees worldwide, we are focused on delivering first-in-class and best-in-class therapeutics toWORKING AT BIOMARIN
There’s something special about BioMarin. Hope. It's where BioMarin's story begins. It's what we work to deliver every day. And it’s what makes being here truly special. Good people doing work that does good. Powerful therapies empowering people’s lives. Rare opportunities sprung from treating rare diseases. EVENTS & PRESENTATIONS : BIOMARIN RBC Capital Markets Global Healthcare Conference. Tuesday, May 11, 2021. BofA 2021 Health Care Conference. Tuesday, May 4, 2021. 7th Annual Truist Securities Life Sciences Summit. Thursday, April 29, 2021. BioMarin Pharmaceutical Inc. First Quarter 2021 Financial Results Conference Call. SEC FILINGS : BIOMARIN Open Statement of changes in beneficial ownership of securities in DOC file. Open Statement of changes in beneficial ownership of securities in PDF file. Open Statement of changes in beneficial ownership of securities in XLS file. 1-25 26-50 51-75 76-85. BIOMARIN RECEIVES FAVORABLE RULING IN THE USE OF EXON 51 SAN RAFAEL, Calif., Sept. 29, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Patent Trial and Appeal Board (PTAB) issued a decision in favor of BioMarin's claims to the use of exon 51 antisense oligonucleotides to BIOMARIN PHARMACEUTICAL INC.ABOUT USPRODUCTS/PIPELINEPATIENTS/PHYSICIANSINVESTORS/MEDIAFUNDING &SUPPORTCAREERS
BioMarin to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, April 29 at 4:30pm ET. March 20, 2021. BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society’s Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide. March 8, 2021.OUR PRODUCTS
Our Products. PALYNZIQ ® (pegvaliase-pqpz) Injection. Brineura ® (cerliponase alfa) Vimizim ® (elosulfase alfa) Kuvan ® (sapropterin dihydrochloride) Naglazyme ® (galsulfase) Aldurazyme ® (laronidase) Our Pipeline. Valoctocogene Roxaparvovec for Severe Hemophilia A.OUR LOCATIONS
BioMarin Pharmaceutical Inc. 770 Lindaro Street. San Rafael, CA 94901. Directions ›. Tel: +1 (415) 506-6700. E-mail: Media Relations. E-mail: Investor Relations. *Please direct all mail to the U.S. mailing address in Novato. INVESTOR RELATIONS : BIOMARIN Email Alerts. May 24, 2021. European Medicines Agency Grants BioMarin's Request for Accelerated Assessment of Valoctocogene Roxaparvovec for Treatment of Severe Hemophilia A. BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Medicines Agency (EMA) has granted its request for accelerated assessment of valoctocogeneGRANTS & DONATIONS
Grants. Grants provide funding for a variety of events, activities, and projects that benefit patients, the scientific or medical community, and/or public health in areas of legitimate interest toBioMarin.
LEADERSHIP TEAM
Under the leadership of Chairman and Chief Executive Officer, Mr. Jean-Jacques Bienaimé, BioMarin’s executive management team includes accomplished leaders with deep and broad executive experience. Supported by a staff of approximately 3,000 employees worldwide, we are focused on delivering first-in-class and best-in-class therapeutics toWORKING AT BIOMARIN
There’s something special about BioMarin. Hope. It's where BioMarin's story begins. It's what we work to deliver every day. And it’s what makes being here truly special. Good people doing work that does good. Powerful therapies empowering people’s lives. Rare opportunities sprung from treating rare diseases. EVENTS & PRESENTATIONS : BIOMARIN RBC Capital Markets Global Healthcare Conference. Tuesday, May 11, 2021. BofA 2021 Health Care Conference. Tuesday, May 4, 2021. 7th Annual Truist Securities Life Sciences Summit. Thursday, April 29, 2021. BioMarin Pharmaceutical Inc. First Quarter 2021 Financial Results Conference Call. SEC FILINGS : BIOMARIN Open Statement of changes in beneficial ownership of securities in DOC file. Open Statement of changes in beneficial ownership of securities in PDF file. Open Statement of changes in beneficial ownership of securities in XLS file. 1-25 26-50 51-75 76-85. BIOMARIN RECEIVES FAVORABLE RULING IN THE USE OF EXON 51 SAN RAFAEL, Calif., Sept. 29, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Patent Trial and Appeal Board (PTAB) issued a decision in favor of BioMarin's claims to the use of exon 51 antisense oligonucleotides toOUR PRODUCTS
Our Products. PALYNZIQ ® (pegvaliase-pqpz) Injection. Brineura ® (cerliponase alfa) Vimizim ® (elosulfase alfa) Kuvan ® (sapropterin dihydrochloride) Naglazyme ® (galsulfase) Aldurazyme ® (laronidase) Our Pipeline. Valoctocogene Roxaparvovec for Severe Hemophilia A.OUR LOCATIONS
BioMarin Pharmaceutical Inc. 770 Lindaro Street San Rafael, CA 94901 Directions › Tel: +1 (415) 506-6700 E-mail: Media Relations E-mail: Investor Relations *Please direct allOUR PIPELINE
Kuvan ® (sapropterin dihydrochloride) Naglazyme ® (galsulfase) Aldurazyme ® (laronidase) Our Pipeline. Valoctocogene Roxaparvovec for Severe Hemophilia A. Vosoritide for Achondroplasia. BMN 307 for Phenylketonuria (PKU) BMN 331 for Hereditary Angioedema (HAE) Compassionate Use Policy. MANUFACTURING EXCELLENCE We take pride in manufacturing complex therapies for the patients who need them most.. BioMarin Technical Operations (TOPS) is an experienced, responsive and agile organization with a proud connection to our patients – developing and manufacturing safe and effective medicines that we consistently deliver to those in need. VIMIZIM® (ELOSULFASE ALFA) FOR MORQUIO A SYNDROME (MPS IVA Vimizim ® (elosulfase alfa) is the first approved enzyme replacement therapy designed to address the underlying cause of Morquio A syndrome, or mucopolysaccharidosis IVA (MPS IVA) — a deficiency in the enzyme N-acetylgalactosamine-6 sulfatase (GALNS). VIMIZIM works at a cellular level to help with deficient enzyme activity. Morquio A is a rare and progressive inherited disease that affects GLOBAL COMPLIANCE & ETHICS BioMarin’s Global Compliance & Ethics Program (the “Program”) is an enterprise-wide global initiative that addresses the seven elements discussed in the OIG Compliance Program Guidance for Pharmaceutical Manufacturers, as well as the tenets of the U.S. Federal SentencingKEVIN EGGAN, PH.D.
Kevin Eggan, Ph.D., joined BioMarin in October 2020 and serves as Group Vice President, Head of Research and Early Development. He is responsible for the execution of BioMarin’s discovery research programs, helping to shape the vision and long-term growth of our company through the oversight of an exceptional research pipeline of first- or best-in-class therapies. EVENTS & PRESENTATIONS : BIOMARIN Our Products. PALYNZIQ ® (pegvaliase-pqpz) Injection for PKU; Brineura ® (cerliponase alfa) for CLN2 Disease; Vimizim ® (elosulfase alfa) for Morquio A Syndrome (MPS IVA); Kuvan ® (sapropterin dihydrochloride) for PKU; Aldurazyme ® (laronidase) for MPS I; Naglazyme ® (galsulfase) for MPS VI; Our Pipeline. Valoctocogene Roxaparvovec for Severe Hemophilia A; Vosoritide forAchondroplasia
BIOMARIN ANNOUNCES PRICING OF UPSIZED $550 MILLION SENIOR SAN RAFAEL, Calif., May 11, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the pricing of $550.0 million aggregate principal amount of 1.25% senior subordinated convertible notes due 2027 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The aggregate principal amount of the BIOMARIN ANNOUNCES CFO SUCCESSION SAN RAFAEL, Calif., Feb. 3, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced the transition of Executive Vice President and Chief Financial Officer Dan Spiegelman.. Mr. Spiegelman will remain as an employee and senior advisor until September 1, 2020 to assist with the transition. After that, he plans to pursue other interests and spend more time with family. * Skip to main navigation * Skip to main content* Skip to Footer
* Clinical Trials
* Contact Us
* Careers
Home
* Our Motivation
* Patient Stories
* Bailey
* Kendra
* Sheri
* Matty
* Diseases & Conditions* PKU
* CLN2 Disease
* MPS VI
* MPS IVA
* MPS I
* Patient & Community Support* Trees of Life
* RARE Scholars
* In the Hemophilia Community* Patient Advocacy
* BioMarin RareConnections™ * Grants & Donations* Resource Library
* Patient Organizations * Professional Organizations* Our Science
* Our Approach
* Technical Expertise * Indication Expansion * Franchise Building* Our Scientists
* Our Publications
* Science Spotlight
* Funding & Support
* Independent Medical Education * Independent Research * Grants & Donations * Publication Data Request* Our Treatments
* Our Products
* PALYNZIQ® (pegvaliase-pqpz) Injection for PKU * Brineura® (cerliponase alfa) for CLN2 Disease * Vimizim® (elosulfase alfa) for Morquio A Syndrome (MPS IVA) * Kuvan® (sapropterin dihydrochloride) for PKU * Aldurazyme® (laronidase) for MPS I * Naglazyme® (galsulfase) for MPS VI* Our Pipeline
* Valoctocogene Roxaparvovec for Severe Hemophilia A * Vosoritide for Achondroplasia * BMN 307 for Phenylketonuria (PKU) * BMN 331 for Hereditary Angioedema (HAE) * Compassionate Use Policy* Our Company
* About Us
* Our History
* Manufacturing Excellence * Message from Chairman and CEO * Global Compliance & Ethics * Corporate Social Responsibility * Diversity, Equity & Inclusion * Environmental Health, Safety and Sustainability (EHS&S)* Leadership Team
* Jean-Jacques Bienaimé * Henry J. Fuchs, M.D.* Jeff Ajer
* G. Eric Davis
* C. Greg Guyer, Ph.D.* Brian R. Mueller
* Lon Cardon, Ph.D.
* Philip Lo Scalzo
* Amy Wireman
* Brinda Balakrishnan, M.D., Ph.D. * Board of Directors * Grants & Donations* Investors & Media
* Press Releases
* Events
* Governance
* Management
* Board of Directors * Committee Composition* Contact the Board
* SEC Filings
* Financials
* 2021
* 2020
* 2019
* 2018
* 2017
* Annual Reports
* Stock Info
* Historical Data
* Resources
* FAQs
* Contact Us
* Email Alerts
Search our website
__
Close
* Our Motivation
* Patient Stories
* Diseases & Conditions * Patient & Community Support* Resource Library
* Our Science
* Our Approach
* Our Scientists
* Our Publications
* Science Spotlight
* Funding & Support
* Our Treatments
* Our Products
* Our Pipeline
* Compassionate Use Policy* Our Company
* About Us
* Corporate Social Responsibility* Leadership Team
* Board of Directors * Grants & Donations* Investors & Media
* Press Releases
* Events
* Governance
* SEC Filings
* Financials
* Stock Info
* Resources
* Privacy Policy
* Terms of Use
* Site Map
* YouTube
* Glossary
2021 BioMarin. All rights reserved. SCIENTIFIC DISCOVERY DRIVEN BY GENETIC DIVERSITY Learn more about our approach to research & developmentLearn More ⌃
CAREERS AT BIOMARIN
OUR FOCUS ON RARE DISEASE GIVES US THE RARE OPPORTUNITY TO TRULYIMPACT LIVES.
Learn More about careers with BioMarin ⌃OUR MOTIVATION
WE ARE INSPIRED AND DRIVEN EVERYDAY BY STORIES LIKE SHERI’S. Learn More about Sheri ⌃ Patient & Community Support TREATMENT IS ONLY THE BEGINNING. We are committed to the communities we treat beyond the therapies wedevelop.
Learn More about our patient support ⌃OUR PIPELINE
WE TAKE ON THE BIGGEST CHALLENGES IN RARE DISEASE. Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it willaddress.
View Now ⌃
News
View All News and press releases⌃*
May 27, 2021 BioMarin to Participate in Two Upcoming Virtual InvestorConferences
*
May 24, 2021 European Medicines Agency Grants BioMarin’s Request for Accelerated Assessment of Valoctocogene Roxaparvovec for Treatment ofSevere Hemophilia A
*
May 19, 2021 BioMarin Provides Highlights of 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec with the Longest Duration of Clinical Experience for a Gene Therapy inHemophilia A
*
May 18, 2021 BioMarin to Participate in Two Upcoming Virtual InvestorConferences
*
May 12, 2021 BioMarin Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting*
May 3, 2021 BioMarin to Participate in Two Upcoming Virtual InvestorConferences
*
April 29, 2021 BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates*
April 28, 2021 Allen Institute and BioMarin Team Up To Develop Gene Therapies For Rare Brain DiseasesHome
* Navigate
* Our Motivation
* Our Science
* Our Treatments
* Our Company
* Investors & Media
* About
* Our History
* Our Products
* Our Pipeline
* Leadership Team
* Board of Directors * Diversity, Equity & Inclusion* Contact
* Global Contact Information* Our Locations
* Report a Product Complaint * Report Adverse Event * Publication Data Request* Funding & Support
* Connect
* Careers
* YouTube
* Privacy Policy
* Terms of Use
* Site Map
* Supplier Information * Slavery Act Statement* Glossary
* Contact Us
2021 BioMarin. All rights reserved. This website uses cookies to improve website functionality. You may delete or block cookies by accessing your preferences. For more information, please see our Privacy Policy and Terms and Conditions . By using this website, you consent to our use of cookies.AcceptDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0